P1446: PHASE I STUDY DATA UPDATE OF PHE885, A FULLY HUMAN BCMA-DIRECTED CAR-T CELL THERAPY MANUFACTURED USING THE T-CHARGETM PLATFORM FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM)

• A. S. Sperling,
• S. Nikiforow,
• B. Derman,
• O. Nadeem,
• C. Mo,
• J. Laubach,
• K. Anderson,
• A. Alonso,
• S.-Y. Im,
• S. Ikwgawa,
• R. Prabhala,
• D. Hernandez Rodriduez,
• H. Daley,
• K. L. Shaw,
• Y. Arihara,
• S. Ansari,
• D. S. Quinn,
• D. Pearson,
• A. Hack,
• L. Treanor,
• D. Bu,
• J. Mataraza,
• L. Rispoli,
• M. Credi,
• J. Ritz,
• A. Jakubowiak,
• S. De Vita,
• N. Munshi

Affiliations

A. S. Sperling

1 Dana-Farber Cancer Institute, Harvard University, Boston

S. Nikiforow

1 Dana-Farber Cancer Institute, Harvard University, Boston

B. Derman

2 Section of Hematology/ONcology, University of Chicago Medical Center, Chicago

O. Nadeem

1 Dana-Farber Cancer Institute, Harvard University, Boston

C. Mo

1 Dana-Farber Cancer Institute, Harvard University, Boston

J. Laubach

1 Dana-Farber Cancer Institute, Harvard University, Boston

K. Anderson

1 Dana-Farber Cancer Institute, Harvard University, Boston

A. Alonso

1 Dana-Farber Cancer Institute, Harvard University, Boston

S.-Y. Im

1 Dana-Farber Cancer Institute, Harvard University, Boston

S. Ikwgawa

1 Dana-Farber Cancer Institute, Harvard University, Boston

R. Prabhala

1 Dana-Farber Cancer Institute, Harvard University, Boston

D. Hernandez Rodriduez

1 Dana-Farber Cancer Institute, Harvard University, Boston

H. Daley

1 Dana-Farber Cancer Institute, Harvard University, Boston

K. L. Shaw

1 Dana-Farber Cancer Institute, Harvard University, Boston

Y. Arihara

1 Dana-Farber Cancer Institute, Harvard University, Boston

S. Ansari

3 Novartis Institutes for BioMedical Research, Cambridge, United States of America

D. S. Quinn

3 Novartis Institutes for BioMedical Research, Cambridge, United States of America

D. Pearson

4 Novartis Institutes for BioMedical Research, Basel, Switzerland

A. Hack

5 Novartis Pharmaceuticals Corporation, East Hanover

L. Treanor

3 Novartis Institutes for BioMedical Research, Cambridge, United States of America

D. Bu

3 Novartis Institutes for BioMedical Research, Cambridge, United States of America

J. Mataraza

3 Novartis Institutes for BioMedical Research, Cambridge, United States of America

L. Rispoli

3 Novartis Institutes for BioMedical Research, Cambridge, United States of America

M. Credi

3 Novartis Institutes for BioMedical Research, Cambridge, United States of America

J. Ritz

6 Harvard University, Boston, United States of America

A. Jakubowiak

2 Section of Hematology/ONcology, University of Chicago Medical Center, Chicago

S. De Vita

3 Novartis Institutes for BioMedical Research, Cambridge, United States of America

N. Munshi

1 Dana-Farber Cancer Institute, Harvard University, Boston